We use cookies

Our website uses essential cookies and, with your consent, additional cookies to measure performance and improve our services. Cookie Policy.

You can change your choice at any time.

MMedXYNews
HomeVideos
MedXY AI/MedXY News/Tag: myelodysplastic syndrome
MedXY News
EnglishTag

myelodysplastic syndrome

Ask MedXY AI
type 2 diabetesclinical trialheart failureimmunotherapyobesitycardiovascular riskatrial fibrillationbiomarkerscritical careclinical trialsHypertensionartificial intelligenceCardiologyoncologypublic healthtype 1 diabetesdiabetesMortalityAlzheimer's diseasecardiovascular diseasebreast cancerepidemiology

Latest news

Tag

Ivosidenib Monotherapy Shows Promise in IDH1 Mutated Myelodysplastic Neoplasm/Syndrome: A Phase 2 Study
Hematology-Oncologytargeted therapyivosidenib

Ivosidenib Monotherapy Shows Promise in IDH1 Mutated Myelodysplastic Neoplasm/Syndrome: A Phase 2 Study

By MedXY|Aug 28, 2026

Ivosidenib monotherapy demonstrates substantial efficacy and safety in IDH1 mutated myelodysplastic neoplasm, especially in treatment-naïve high-risk patients, offering a new therapeutic option.

Unveiling Atelis Syndrome: SLF2 and SMC5 Dysfunction as Drivers of Hematopoietic Stem Cell Aging and Myelodysplastic Syndrome Predisposition
Hematology-Oncologyinherited bone marrow failure
© 2026 MedXY
Contact usAbout usPrivacy PolicyMedXY story
Atelis Syndrome

Unveiling Atelis Syndrome: SLF2 and SMC5 Dysfunction as Drivers of Hematopoietic Stem Cell Aging and Myelodysplastic Syndrome Predisposition

By MedXY|Aug 10, 2026

Dysfunction in SLF2 and SMC5 causes premature hematopoietic stem cell aging, bone marrow failure, and early-onset myelodysplastic syndrome in Atelis Syndrome, defining a novel inherited bone marrow failure disorder.

Unraveling MDM4 Haploinsufficiency: A Novel TP53-Dependent Mechanism Driving Bone Marrow Failure Syndromes
Hematology-Oncologybone marrow failureHematopoiesis

Unraveling MDM4 Haploinsufficiency: A Novel TP53-Dependent Mechanism Driving Bone Marrow Failure Syndromes

By MedXY|Jul 17, 2026

MDM4 haploinsufficiency activates p53, causing diverse bone marrow failure phenotypes and hypocellular MDS, highlighting the pivotal MDM4-p53 axis in hematopoietic regulation and potential targets for intervention.

Long-Term Outcomes and Durability of Exceptional Responses to PARP Inhibitors in Recurrent Platinum-Sensitive Ovarian Cancer
newsExceptional responsePlatinum-sensitive

Long-Term Outcomes and Durability of Exceptional Responses to PARP Inhibitors in Recurrent Platinum-Sensitive Ovarian Cancer

By MedXY|Aug 18, 2026

This international study reveals that many patients with platinum-sensitive recurrent ovarian cancer achieve durable, progression-free survival exceeding 5 years on PARP inhibitors, even after treatment discontinuation, with a low risk of s

Azacitidine Shows Promising Efficacy and Safety in Treating VEXAS Syndrome: Insights from a Large-Scale Retrospective FRENVEX Study
Hematology-Oncologyazacitidinemyelodysplastic syndrome

Azacitidine Shows Promising Efficacy and Safety in Treating VEXAS Syndrome: Insights from a Large-Scale Retrospective FRENVEX Study

By MedXY|Oct 14, 2025

A retrospective study of 88 patients with genetically confirmed VEXAS syndrome reveals that azacitidine improves inflammatory symptoms, cytopenias, and reduces UBA1 mutant clone burden with an acceptable safety profile, supporting its use a

Oral Decitabine and Cedazuridine Maintenance Post-HSCT: Promising Strategy in High-Risk AML and MDS
Clinical Updatesacute myeloid leukaemiahematopoietic stem-cell transplantation

Oral Decitabine and Cedazuridine Maintenance Post-HSCT: Promising Strategy in High-Risk AML and MDS

By MedXY|Oct 9, 2025

A phase 2 trial demonstrates that oral hypomethylating agent ASTX727, with optional donor lymphocyte infusion, shows encouraging disease-free survival and manageable safety after stem-cell transplantation in very high-risk acute myeloid leu

Oral Decitabine and Cedazuridine as Maintenance Therapy Post-HSCT in Very High-Risk AML and MDS: Insights from the GFM-DACORAL-DLI Phase 2 Trial
Clinical Updatesacute myeloid leukemiahematopoietic stem-cell transplantation

Oral Decitabine and Cedazuridine as Maintenance Therapy Post-HSCT in Very High-Risk AML and MDS: Insights from the GFM-DACORAL-DLI Phase 2 Trial

By MedXY|Oct 9, 2025

A phase 2 trial demonstrates that oral decitabine and cedazuridine maintenance following hematopoietic stem-cell transplantation may improve disease-free survival in very high-risk AML and MDS patients with manageable safety.

Bexmarilimab Plus Azacitidine in High-Risk Myelodysplastic Syndrome and Relapsed/Refractory Acute Myeloid Leukaemia: Phase 1 Dose-Escalation Results
Clinical Updatesacute myeloid leukaemiaazacitidine

Bexmarilimab Plus Azacitidine in High-Risk Myelodysplastic Syndrome and Relapsed/Refractory Acute Myeloid Leukaemia: Phase 1 Dose-Escalation Results

By MedXY|Oct 1, 2025

The combination of bexmarilimab and azacitidine shows manageable safety and promising efficacy in high-risk myelodysplastic syndrome and relapsed/refractory acute myeloid leukaemia, supporting further investigation.

Ask MedXY AI

Most popular

Intimate Health
Five Benefits for Women Continuing Sexual Activity After Menopause
Intimate Health
Why Some Women Have a Strong Sex Drive—And Why Men Shouldn't Worry About It
Nursing & care
How often should a couple have sex?
Intimate Health
Classic Intimacy Recommendations: How to Help Women Reach Orgasm and Enjoy Mutual Pleasure
Intimate Health
What Makes a Woman "Physiologically Addicted" Is Never Money, But These Two Relationship Qualities